Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sosimerasib vs Docetaxel in KRAS G12C-Mutant NSCLC
NCT07242274Phase 3Not yet recruiting
- Sponsor
- Jemincare
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sosimerasib in non-small cell lung cancer (NSCLC), sponsored by Jemincare. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sosimerasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07242274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07242274.